A director at Ambea AB bought 75,000 shares at 126.000SEK and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
As part of the rotation of our coverage, we are terminating the coverage with recommendation of Securitas. We will continue to follow the newsflow of the issuer in the Credit Morning. Our previous credit opinion was Positive and our previous market recommendations were Buy on SECUSS 2027 & 2029 and Neutral on SECUSS 2028 bonds. We plan to initiate the coverage of new issuers soon.
Dans le cadre de la rotation du suivi de nos valeurs, nous arrêtons la couverture avec recommandation de Securitas. Nous continuerons de suivre le newsflow de cet émetteur dans le Morning crédit. Notre précédent avis crédit était Positif et nos précédentes recommandations de marché étaient Achat sur les obligations SECUBSS 2027 et 2029 et Neutre sur la souche 2028. Nous comptons prochainement initier la couverture de nouveaux émetteurs.
A director at Securitas AB bought 3,500 shares at 142.600SEK and the significance rating of the trade was 63/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Yesterday, post-market, XVIVO confirmed a delay in CE mark clearance for its heart perfusion solution and supplement, citing an extended consultation process with EU regulatory bodies. While the Heart Assist Transport device and perfusion set have been cleared, the remaining component, its propriet
A director at Modern Times Group AB bought 17,540 shares at 102.000SEK and the significance rating of the trade was 78/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
Yesterday, XVIVO enroled the first patient under the CAP study for heart technology in the US, allowing its continued use in up to 60 patients following the successful completion of the US pivotal study back in November 2024, with 1-year follow-up data to be analysed before PMA submission. This new
Following the broad Q2 miss, we revisited our expectations across all business segments, leading to a 2025E sales cut, now expecting 1.1% YoY growth instead of 18%. The major cut comes from the US Lung outlook as the destocking from their largest US client (which represented ~50% of US EVLP sales a
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.